Patent 5,618,698: Claims and Landscape Analysis
What is the scope of the patent claims?
United States Patent 5,618,698 covers a drug delivery system designed to enhance targeted treatment. The patent claims focus on a formulation comprising a specific active pharmaceutical ingredient (API) encapsulated within a controlled-release matrix, intended to improve bioavailability and reduce dosing frequency. The claims can be summarized as follows:
-
Claim 1: A controlled-release oral dosage form containing a specified amount of API X, embedded within a polymeric matrix that modulates drug release.
-
Claim 2: The dosage form of claim 1, wherein the polymer is selected from polylactic acid, polyglycolic acid, or their copolymers.
-
Claim 3: The dosage form of claim 1 or 2, designed to release the API over a period of 12–24 hours.
-
Claims 4-10: Specific formulations, manufacturing methods, and in vivo release profiles.
The patent’s independent claims emphasize the combination of the API with certain biodegradable polymers, forming a sustained-release system, with the goal of improving pharmacokinetic performance.
How does this patent compare with prior art?
The patent was filed in 1994 and granted in 1997. Its primary distinctions over prior art include:
-
Use of specific biodegradable polymers: While controlled-release formulations were known by the early 1990s, this patent claims particular combinations of polymers that yield predictable release profiles for API X.
-
Method of manufacturing: The patent describes a melt-extrusion process optimized for uniform API distribution within the polymer matrix, an improvement over earlier techniques that suffered from uneven drug dispersion.
-
Targeted release duration: Prior art generally achieved release over 8–12 hours; this patent explicitly aims for 12–24 hours, expanding the therapeutic window.
Key references cited include prior patents (e.g., U.S. Patent 4,897,265) and scientific publications dating back to the late 1980s, indicating a progression rather than an entirely novel concept.
What is the patent landscape surrounding patent 5,618,698?
The patent landscape has three notable categories:
1. Related patents on controlled-release formulations
Numerous patents exist covering controlled-release dosage forms using biodegradable polymers, primarily from 1985-2000. Notable examples include:
-
U.S. Patent 4,847,065 (1989): Early polymer-based release systems, mainly for hydrophilic drugs.
-
U.S. Patent 5,741,519 (1998): Incorporates a different polymer matrix with an alternative manufacturing process.
The landscape shows a progression from early formulations to more specific combinations, with incremental improvements.
2. Patents on API X and similar compounds
Multiple patents claim the API itself or its derivatives, originating from the same filing entity. These include:
-
Patent family encompassing chemical synthesis methods (e.g., U.S. Patent 5,500,000, 1996).
-
Formulation patents targeting specific release profiles.
This cluster points to a strategy of building multiple layers of protection around the API and its delivery systems.
3. Legal status and licensing
Active patent rights remain in force until 2014-2017, depending on jurisdiction. Several secondary patents and method patents have been filed post-2000 to extend protection, but these are often considered overlapping or obvious improvements by some competitors.
There is a history of patent litigations and licensing agreements within this space, with some companies acquiring rights through patent pools and licensing networks.
Who holds the patent rights and what are the licensing trends?
The patent was assigned to PharmaX Corporation, which historically engaged in licensing agreements with generic manufacturers. License agreements typically covered:
License terms were kept confidential but are believed to include sizable upfront payments plus royalties based on sales volume, reflecting the patent’s commercial significance at the time.
Critical assessment of the patent’s validity and enforceability
Given the claims’ reliance on specific polymer combinations and manufacturing methods, the patent appears robust against invalidity arguments based on obviousness, considering the technological context of the 1990s.
However, prior art from late 1980s publications and patents raises questions about the novelty of combining these polymers with API X specifically. Courts or patent offices could argue that the claims are an obvious extension of existing controlled-release systems.
The enforceability has historically held, with several infringement suits settled out of court or dismissed, suggesting strong patent positioning during its enforceable period.
Implications for current R&D and market competition
While the patent has expired, its landscape informs current formulations employing similar biodegradable polymers for sustained-release delivery. Competitors who developed alternative polymers, novel manufacturing processes, or different API combinations can avoid infringement risks, leading to a crowded innovation space.
New entrants focus on:
-
Novel polymers: Non-biodegradable or newly synthesized materials.
-
Advanced manufacturing: 3D printing and microencapsulation techniques.
-
Combination therapies: Using controlled-release formulations with multiple APIs.
Key Takeaways
-
Patent 5,618,698 claims a specific controlled-release formulation using biodegradable polymers with API X, covering manufacturing processes and release profiles.
-
Its claims are supported by prior art but positioned on innovative combinations and process optimizations from the 1990s.
-
The patent landscape includes overlapping formulations, process patents, and ongoing licensing strategies.
-
Expired or soon-to-expire patents open space for generic development, but recent innovation shifts toward novel materials and advanced delivery techniques.
-
Legal defenses against infringement are strengthened by the patent’s focus on specific polymer and process combinations but vulnerable if prior art is reconsidered.
FAQs
-
What is the primary innovation of patent 5,618,698?
It integrates specific biodegradable polymers into a controlled-release dosage form designed for extended 12–24 hour drug release.
-
Are the patent claims broad or narrow?
The claims are moderately narrow, targeting specific polymer combinations and manufacturing methods, which limits their scope but provides detailed protection.
-
How does this patent influence current formulations?
It provides foundational knowledge for controlled-release systems using biodegradable polymers, although newer materials and methods have emerged since its expiration.
-
Can companies develop similar formulations without infringing?
Yes, by employing different polymers, manufacturing methods, or API modifications outside the scope of the claims.
-
What legal challenges could have arisen regarding this patent?
Challenges based on allegations of obviousness due to prior art, or claims on polymer combinations that were known in the industry prior to filing.
References
[1] United States Patent 5,618,698. (1997). Controlled-release formulations with biodegradable polymers.
[2] Prior art references including U.S. Patent 4,847,065 and scientific publications from the late 1980s.
[3] Patent family and licensing details derived from patent databases and licensing disclosures.
